JAZZ Annual EBITDA
$1.23 B
+$681.13 M+124.99%
31 December 2023
Summary:
As of January 22, 2025, JAZZ annual earnings before interest, taxes, depreciation & amortization is $1.23 billion, with the most recent change of +$681.13 million (+124.99%) on December 31, 2023. During the last 3 years, it has risen by +$573.01 million (+87.74%). JAZZ annual EBITDA is now at all-time high.JAZZ EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ Quarterly EBITDA
$424.74 M
+$61.76 M+17.01%
30 September 2024
Summary:
As of January 22, 2025, JAZZ quarterly earnings before interest, taxes, depreciation & amortization is $424.74 million, with the most recent change of +$61.76 million (+17.01%) on September 30, 2024. Over the past year, it has increased by +$91.17 million (+27.33%). JAZZ quarterly EBITDA is now at all-time high.JAZZ Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ TTM EBITDA
$1.31 B
+$91.17 M+7.50%
30 September 2024
Summary:
As of January 22, 2025, JAZZ TTM earnings before interest, taxes, depreciation & amortization is $1.31 billion, with the most recent change of +$91.17 million (+7.50%) on September 30, 2024. Over the past year, it has increased by +$492.80 million (+60.55%). JAZZ TTM EBITDA is now at all-time high.JAZZ TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +125.0% | +27.3% | +60.5% |
| 3 y3 years | +87.7% | +27.3% | +60.5% |
| 5 y5 years | +48.7% | +27.3% | +60.5% |
JAZZ EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +125.0% | at high | +450.6% | at high | +139.8% |
| 5 y | 5-year | at high | +125.0% | at high | +444.1% | at high | +139.8% |
| alltime | all time | at high | +1056.0% | at high | +444.1% | at high | +812.4% |
Jazz Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $424.74 M(+17.0%) | $1.31 B(+7.5%) |
| June 2024 | - | $362.99 M(+59.3%) | $1.22 B(+4.1%) |
| Mar 2024 | - | $227.90 M(-21.7%) | $1.17 B(-4.8%) |
| Dec 2023 | $1.23 B(+125.0%) | $291.05 M(-12.7%) | $1.23 B(+50.6%) |
| Sept 2023 | - | $333.57 M(+6.0%) | $813.88 M(+25.4%) |
| June 2023 | - | $314.83 M(+9.8%) | $649.24 M(+12.9%) |
| Mar 2023 | - | $286.61 M(-336.6%) | $574.82 M(+5.5%) |
| Dec 2022 | $544.93 M(-24.1%) | -$121.14 M(-171.7%) | $544.93 M(-37.7%) |
| Sept 2022 | - | $168.94 M(-29.7%) | $874.45 M(-2.7%) |
| June 2022 | - | $240.41 M(-6.4%) | $898.83 M(+21.6%) |
| Mar 2022 | - | $256.72 M(+23.2%) | $739.10 M(+2.9%) |
| Dec 2021 | $718.41 M(+10.0%) | $208.39 M(+7.8%) | $718.41 M(-4.7%) |
| Sept 2021 | - | $193.31 M(+139.6%) | $754.07 M(-8.9%) |
| June 2021 | - | $80.67 M(-65.8%) | $827.82 M(-18.2%) |
| Mar 2021 | - | $236.03 M(-3.3%) | $1.01 B(+55.0%) |
| Dec 2020 | $653.05 M(-27.2%) | $244.05 M(-8.6%) | $653.05 M(+1.1%) |
| Sept 2020 | - | $267.06 M(+0.6%) | $645.96 M(+11.8%) |
| June 2020 | - | $265.38 M(-315.0%) | $577.83 M(-0.3%) |
| Mar 2020 | - | -$123.43 M(-152.1%) | $579.73 M(-35.3%) |
| Dec 2019 | $896.72 M(+8.7%) | $236.96 M(+19.1%) | $896.72 M(+0.2%) |
| Sept 2019 | - | $198.92 M(-25.6%) | $894.96 M(-4.3%) |
| June 2019 | - | $267.28 M(+38.1%) | $934.95 M(+6.8%) |
| Mar 2019 | - | $193.56 M(-17.7%) | $875.44 M(+6.2%) |
| Dec 2018 | $824.69 M(+20.6%) | $235.20 M(-1.6%) | $824.69 M(+4.8%) |
| Sept 2018 | - | $238.92 M(+15.0%) | $786.55 M(+15.3%) |
| June 2018 | - | $207.77 M(+45.5%) | $682.24 M(+2.8%) |
| Mar 2018 | - | $142.81 M(-27.5%) | $663.36 M(-3.0%) |
| Dec 2017 | $684.03 M(-3.4%) | $197.05 M(+46.4%) | $684.03 M(-0.5%) |
| Sept 2017 | - | $134.61 M(-28.7%) | $687.20 M(-4.2%) |
| June 2017 | - | $188.90 M(+15.6%) | $717.03 M(-1.3%) |
| Mar 2017 | - | $163.47 M(-18.4%) | $726.13 M(+2.5%) |
| Dec 2016 | $708.17 M(+17.9%) | $200.23 M(+21.8%) | $708.17 M(+10.1%) |
| Sept 2016 | - | $164.44 M(-16.9%) | $643.10 M(+0.8%) |
| June 2016 | - | $197.99 M(+36.1%) | $637.89 M(+6.2%) |
| Mar 2016 | - | $145.51 M(+7.7%) | $600.50 M(-0.1%) |
| Dec 2015 | $600.91 M(+77.8%) | $135.16 M(-15.1%) | $600.91 M(-4.9%) |
| Sept 2015 | - | $159.23 M(-0.9%) | $631.71 M(+10.9%) |
| June 2015 | - | $160.60 M(+10.1%) | $569.49 M(+10.0%) |
| Mar 2015 | - | $145.91 M(-12.1%) | $517.91 M(+53.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2014 | $337.95 M(-18.9%) | $165.96 M(+71.1%) | $337.95 M(+17.7%) |
| Sept 2014 | - | $97.02 M(-11.0%) | $287.03 M(-7.5%) |
| June 2014 | - | $109.02 M(-420.2%) | $310.42 M(+5.5%) |
| Mar 2014 | - | -$34.05 M(-129.6%) | $294.32 M(-29.4%) |
| Dec 2013 | $416.96 M(+55.3%) | $115.04 M(-4.5%) | $416.96 M(+7.1%) |
| Sept 2013 | - | $120.41 M(+29.6%) | $389.46 M(+12.8%) |
| June 2013 | - | $92.93 M(+4.9%) | $345.38 M(+12.3%) |
| Mar 2013 | - | $88.59 M(+1.2%) | $307.62 M(+14.6%) |
| Dec 2012 | $268.45 M(+99.7%) | $87.54 M(+14.7%) | $268.47 M(+21.8%) |
| Sept 2012 | - | $76.33 M(+38.4%) | $220.42 M(+23.4%) |
| June 2012 | - | $55.17 M(+11.6%) | $178.64 M(+12.2%) |
| Mar 2012 | - | $49.44 M(+25.2%) | $159.28 M(+18.5%) |
| Dec 2011 | $134.41 M(+147.9%) | $39.49 M(+14.3%) | $134.41 M(+22.0%) |
| Sept 2011 | - | $34.55 M(-3.5%) | $110.21 M(+19.6%) |
| June 2011 | - | $35.81 M(+45.7%) | $92.15 M(+33.2%) |
| Mar 2011 | - | $24.57 M(+60.8%) | $69.20 M(+27.6%) |
| Dec 2010 | $54.21 M(+116.6%) | $15.28 M(-7.3%) | $54.21 M(+2.8%) |
| Sept 2010 | - | $16.49 M(+28.4%) | $52.72 M(+24.5%) |
| June 2010 | - | $12.85 M(+34.0%) | $42.36 M(+6.6%) |
| Mar 2010 | - | $9.59 M(-30.5%) | $39.73 M(+58.8%) |
| Dec 2009 | $25.03 M(-119.9%) | $13.79 M(+125.0%) | $25.03 M(-462.2%) |
| Sept 2009 | - | $6.13 M(-40.0%) | -$6.91 M(-81.2%) |
| June 2009 | - | $10.22 M(-299.7%) | -$36.69 M(-59.0%) |
| Mar 2009 | - | -$5.12 M(-71.8%) | -$89.53 M(-28.7%) |
| Dec 2008 | -$125.58 M(-2.1%) | -$18.14 M(-23.3%) | -$125.58 M(-23.2%) |
| Sept 2008 | - | -$23.65 M(-44.5%) | -$163.51 M(+5.5%) |
| June 2008 | - | -$42.62 M(+3.5%) | -$155.04 M(+1.6%) |
| Mar 2008 | - | -$41.16 M(-26.6%) | -$152.56 M(+19.0%) |
| Dec 2007 | -$128.25 M(+89.3%) | -$56.08 M(+269.5%) | -$128.25 M(-30.1%) |
| Sept 2007 | - | -$15.18 M(-62.2%) | -$183.41 M(+17.2%) |
| June 2007 | - | -$40.14 M(+138.1%) | -$156.56 M(+49.5%) |
| Mar 2007 | - | -$16.86 M(-84.8%) | -$104.75 M(+34.2%) |
| Dec 2006 | -$67.74 M(+31.0%) | -$111.23 M(-1052.9%) | -$78.05 M(+94.9%) |
| Sept 2006 | - | $11.67 M(0.0%) | -$40.04 M(-13.6%) |
| June 2006 | - | $11.67 M(+18.7%) | -$46.35 M(-12.0%) |
| Mar 2006 | - | $9.84 M(-113.4%) | -$52.67 M(-7.8%) |
| Dec 2005 | -$51.70 M | -$73.23 M(-1465.9%) | -$57.14 M(-455.3%) |
| Sept 2005 | - | $5.36 M(0.0%) | $16.08 M(+50.0%) |
| June 2005 | - | $5.36 M(0.0%) | $10.72 M(+100.0%) |
| Mar 2005 | - | $5.36 M | $5.36 M |
FAQ
- What is Jazz Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals annual EBITDA year-on-year change?
- What is Jazz Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Jazz Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals TTM EBITDA year-on-year change?
What is Jazz Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of JAZZ is $1.23 B
What is the all time high annual EBITDA for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $1.23 B
What is Jazz Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, JAZZ annual earnings before interest, taxes, depreciation & amortization has changed by +$681.13 M (+124.99%)
What is Jazz Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of JAZZ is $424.74 M
What is the all time high quarterly EBITDA for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $424.74 M
What is Jazz Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, JAZZ quarterly earnings before interest, taxes, depreciation & amortization has changed by +$91.17 M (+27.33%)
What is Jazz Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of JAZZ is $1.31 B
What is the all time high TTM EBITDA for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.31 B
What is Jazz Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, JAZZ TTM earnings before interest, taxes, depreciation & amortization has changed by +$492.80 M (+60.55%)